PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+24.13%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$2.86B
AUM Growth
+$2.86B
(+9.4%)
Cap. Flow
-$206M
Cap. Flow
% of AUM
-7.22%
Top 10 Holdings %
Top 10 Hldgs %
68.12%
Holding
42
New
7
Increased
15
Reduced
7
Closed
11
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$48.5M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$47M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$45M |
| 4 |
Nuvalent
NUVL
|
$43.8M |
| 5 |
Janux Therapeutics
JANX
|
$38M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$150M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$95.3M |
| 3 |
Ascendis Pharma
ASND
|
$90.6M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$79.7M |
| 5 |
Disc Medicine
IRON
|
$59.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuvalent
NUVL
$5.52B
| $512M | 17.3% | 5,000,000 +428,322 | +9% | +$43.8M |
|
2
Arcellx
ACLX
$3.85B
| $334M | 11.3% | 4,000,000 +151,905 | +4% | +$12.7M |
|
3
argenx
ARGX
$43.6B
| $260M | 8.81% | 480,374 -57,765 | -11% | -$31.3M |
|
4
Revolution Medicines
RVMD
$7.1B
| $241M | 8.15% | 5,314,089 +55,000 | +1% | +$2.49M |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $129M | 4.35% | 2,516,686 +3,384 | +0.1% | +$173K |
|
6
Merus
MRUS
$4.98B
| $123M | 4.15% | 2,454,917 +435,103 | +22% | +$21.7M |
|
|
7
Janux Therapeutics
JANX
$1.37B
| $109M | 3.69% | 2,400,574 +836,122 | +53% | +$38M |
|
8
Kura Oncology
KURA
$686M
| $84.6M | 2.86% | 4,331,321 -208,060 | -5% | -$4.07M |
|
9
Tarsus Pharmaceuticals
TARS
$2.47B
| $80.3M | 2.72% | 2,440,445 +5,029 | +0.2% | +$165K |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $74.4M | 2.52% | 2,789,172 +463,723 | +20% | +$12.4M |
|
|
11
Disc Medicine
IRON
$2.07B
| $73.6M | 2.49% | 1,497,720 -1,206,998 | -45% | -$59.3M |
|
12
Vaxcyte
PCVX
$4B
| $71.7M | 2.43% | 627,732 +530 | +0.1% | +$60.6K |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $65.9M | 2.23% | 2,895,689 -660 | -0% | -$15K |
|
14
Olema Pharmaceuticals
OLMA
$375M
| $65.7M | 2.22% | 5,503,600 -2,400,000 | -30% | -$28.7M |
|
15
Arvinas
ARVN
$568M
| $57.6M | 1.95% | 2,339,961 -98,188 | -4% | -$2.42M |
|
16
Y-mAbs Therapeutics
YMAB
$388M
| $53.7M | 1.82% | 4,086,346 +215,752 | +6% | +$2.84M |
|
17
Cogent Biosciences
COGT
$1.69B
| $49.8M | 1.68% | 4,609,762 +985,420 | +27% | +$10.6M |
|
|
18
Vera Therapeutics
VERA
$1.38B
| $48.5M | 1.64% | +1,096,851 | New | +$48.5M |
|
|
19
MoonLake Immunotherapeutics
MLTX
$3.54B
| $47M | 1.59% | +931,480 | New | +$47M |
|
|
ONC
20
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $45M | 1.52% | +200,336 | New | +$45M |
|
21
Immatics
IMTX
$619M
| $44.6M | 1.51% | 3,904,862 +482,897 | +14% | +$5.51M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $41.2M | 1.39% | 701,817 +371,817 | +113% | +$21.8M |
|
23
Immunovant
IMVT
$2.56B
| $38.9M | 1.31% | 1,362,827 | – | – |
|
24
Cullinan Oncology
CGEM
$445M
| $38.9M | 1.31% | 2,321,013 +778,208 | +50% | +$13M |
|
25
Spyre Therapeutics
SYRE
$996M
| $37.3M | 1.26% | +1,267,581 | New | +$37.3M |
|